DOCSLIB.ORG

Abortive Antimigraine Medication 123 Absenteeism 25, 29

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abortive Antimigraine Medication 123 Absenteeism 25, 29 Index abortive antimigraine medication 123 blood oxygenation-level dependant signal absenteeism 25, 29 8,9,80 acetylcholine 74 BMS-181885 60 adhesion molecule, endothelial 122 bosetan 59, 137 a-adrenergic-2 receptor 101 brain arteriole, receptors for corticotrophin­ A5-fiber 91, 161 releasing hormone 122 albumin, 99-technetium labeled 76 brain spectroscopy 10 allodynia 4, 77, 162 brainstem 12, 13 allopregnanolone 74 y-aminobutyric acid 73, 99 calcitonin gene-related peptide 2,4,5, 18, 55, amitriptyline 151 71,92,96, 119, 133, 141, 161 amyl nitrite 6, 7 calcium channelopathy 12 analgesic, non-steroidal anti-inflammatory calcium-channel blocker 152 71,149 capsaicin 12, 68, 101, 123, 133 antalarmin 119, 123 carbon dioxide 6 antidepressant, tricyclic 151 5-carboxamide tryptamine 17, 136 antidromic trigeminal ganglion stimulation 119 carotid blood flow 17 antidromic vasodilation 2 cat saphenous vein 17 anxiety 23 catecholaminergic nerve fiber 115 arteriovenous anastomoses 17,78,133 cavernous sinus 76 ascending reticular activating system 12 cerebral blood flow 7, 8, 12 associated migraine symptom 12 cerebral circulation 10, 11 avitriptan 60 cerebral cortex 11 axon reflex flare 2 cerebral vasoconstriction 6, 10, 11 azatadine 119, 124 cerebral vasodilation 6,7,10, 11 cerebrospinal fluid 1,5,6, 119 baclofen 74 cervical ganglion stimulation 121 benzoylamino-benzopyran compound 137 C-fiber 91, 121, 161 beta-blocker 147 c-fos expression 69, 80 BI-BN4096BS 141 chiropractic manipulation 27 bicuculline 74 chlorophenylpiperazine 98 165 Index cholinergic nerve fiber 115 extracranial arterial vasodilation 1, 10 chronic paroxysmal hemicrania 75 extracranial artery 1,3, 10, 15 cingulate cortex 12, 13 extracranial tissue 11, 139 duster headache 76, 121 extracranial vasodilation 12 cortical spreading depression 65, 79, 98 extravasation receptor 136 corticotrophin-releasing hormone 119, 122-124 familial hemiplegic migraine 80 CP-122288 59,97,135-137 fiberoptic probe 122 cutaneous allodynia 77, 162 FK-888 140 cydic AMP 72 flunarizine 152 cydo-oxygenase 1 100, 149 fluoxetine 151 cyproheptadine 150 flushing 122 depression 23, 65, 79, 98 GABA-A receptor 100 diencephalon 120 gamma-aminobutyric acid (GABA) 151 diffusion-weighted echo-planar magnetic gluceptate, 99-technetium 120 resonance imaging 79 glutamate 80 dihydroergotamine 14,16,17 glutamic acid decarboxylase 74 disodium cromoglycate 120 GR-205171 78,139 dog saphenous vein 17 granulocyte infiltration 122 dorsal horn 122 dorsal root ganglion 122 headache, daily 23 dura mater 65,115, 133 hemicrania, chronic paroxysmal 75 dural blood vessel, diameter 79 hemiplegic migraine, familial 80 dural inflammation 162 histamine/serotonin-receptor antagoist 119, 124 histamine-3 receptor 101,119 electrical stimulation 69,77 histamine-3-receptor agonist 124 emergency room use 27 hospitalization 27 emotional stress 119 hyperalgesia 162 endothelial adhesion molecule 122 hyperemia, reactive 8 endothelin 59,137 hypothalamic-pituitary-adrenal axis 119 endothelin receptor 13 7 hypothalamus 115 endothelin-receptor antagonist 137 enkephalin 5, 6 ICAM-l 152 epidemiology of migraine 21 IL-2-receptor 122 epilepsy 23 IL-6 119 episodic ataxia type 2 80 immobilization stress 119, 124 ergot 14,17,18,70 indomethacin 150 ergot, modes of action 14 inflammation 2,10-12, 14, 18, 56, 65, 76, 77, ergotamine 1, 4, 14, 15, 133 91,115,119,124,133,162 exercise-induced migraine aura 9 inflammatory peptide, source 161 external jugular vein 4,5, 17, 18 inflammatory soup 76 166 Index interleukin (IL)-3, -4 and -6 115 migraine pathogenesis, sequential concept 10 intracranial arteries 1 migraine prevention 141, 147 intracranial histamine 115 migraine process 11, 12 intracranial sensitivity, increased 162 migraine trigger 11, 13 intravital microscopy 79 migraine with aura 1,7-11 ischemia 80 migraine without aura 8, 10-12 itching 122 migrainous infarction 10 migrainous vasodilation 2 L-758298 139, 140 mononuclear leukocyte 122 lanepitant 138,141 muscimol 74 laser beam excitation 122 leaner mouse 80 n-methyl-d-aspartate (NMDA) 151 leukemic mast cell 123 nerve fiber 115 leukocyte 122 nerve growth factor 99 limbic system 12 neurogenic inflammation 2, 10-12, 14, 18,56, localization of mast cells, with neurons 65,91,119,124,133 115 neurogenic vasodilation 58,97, 133 LY-303870 (Ianepitant) 138,139,141 neuroimaging technique 162 LY-334370 97, 135, 136, 140 neuroinflammatory disorder 119 neurokinin A 3,93, 161 mama 23 neurokinin B 93 mast cell, allergic reaction 115 neurokinin-1 receptor 140 mast cell hyperplasia 121 neurokinin-I-receptor antagonist 57, 78, 124 mast cell stabilizer 120 neurokinin-I-receptor knockout mice 124 mastocytosis 121 neuronal dysfunction 119 meninge 115 neuropeptide, sensory 119, 124 mesencephalon 12-14 neuropeptide y 93 meta-chlorophenylpiperazine 98 neuropeptide K 93 nU-methylhistamine 119 neuropeptide Y-1 75 methysergide 150 neurosensitizing molecule 119 migraine abortion, pharmacology 14 NF-KB 149 migraine attack 10, 11 NG-nitro-L-arginine 122 migraine attack, pathogenesis 10 nitric oxide 59, 70, 101, 119, 137 migraine aura 6, 8-12, 65, 79 nitroglycerin 69, 101 migraine aura, pathogenesis 6 non-prescription medication 25,27 migraine aura without headache 12 non-steroidal anti-inflammatory analgesic migraine generator 12, 13 71,149 migraine headache 1, 10, 13-15, 18, 119 nucleus caudalis 124 migraine headache, pathogenesis 1, 10, 11, 124 occipital cortex 8 migraine mechanism 65 oligemia 8 migraine pathogenesis, parallel concept 11 otic ganglion 75 167 Index pain medication 25 self-relaxation 123 pain threshold 3-5,18 sensitization 77, 161 pain transmission 124 sensory neuron 119 parasympathetic nervous system 72, 73 sensory neuropeptide 119,124 parasympathetic sphenopalatine ganglion sensory nucleus of the trigeminal nerve 124 stimulation 121 serotonin 73, 96, 124 peptidergic nerve fiber 115 serotonin-l A receptor 98,146 periaqueductal gray 14 serotonin-lB receptor 58,70,73,97, 134 peri-infarct depolarization 80 serotonin IBID-receptor agonist 58, 134 peripheral nerve fiber 124 serotonin-lD receptor 134 phonophobia 12 serotonin-IF receptor 70,97 photophobia 12 serotonin-IF-receptor agonist 97 physical stress 119 serotonin-2B receptor 73,98, 146 pizotifen 150 serotonin I-like receptor 17 plasma-protein extravasation 67,75,92, 124, serotonin receptor 17,58,70,73,97,98,134, 133, 137, 140 146 PNU-142633 134-136 serotonin-7 receptor 146 positron emission tomography 12-14 single-photon emission computed tomography postjunctional inhibitor 133 76 prejuctional inhibitor 133, 134 social causation 23 pro-inflammatory action 122 social selection 24 propranolol 147 socioeconomic status 23, 24 prostaglandin 72, 100 somatostatin 101 prostaglandin E2 72 specialist consultation 26 prostanoid receptor EP3 101 sphenopalatine ganglion 75 spreading depression 6, 10, 12, 119, 124, 137 quality of life 24, 25 spreading excitation 10, 12 stress 119, 124 race 22 stress hormone 124 reactive hyperemia 8 stroke 23 reactive vasodilation 10, 11 substance P 2,55,68,93,96, 115, 133, 140, relaxation therapy 27 161 retina 75, 162 sumatriptan 12,17,18,97,123,133 rizatriptan 17, 123 sumatriptan analogue 135 RO-470203 137, 138 superficial temporal artery 2,3,14,16,17, superior sagittal sinus 71,77 SB-220453 137 sympathetic ganglion 122 scanning electron microscopy 115 sympathetic nervous system 2, 12 scintillating scotoma 6, 7 selective serotonin re-uptake inhibitor 151 tachykinin 93 selective serotonin-lD-receptor agonist 134 99-technetium labeled albumin 76 selective serotonin-IF-receptor agonist 135 99-technetium-gluceptate 120 168 Index temporal artery 2 urine 123 tension-type headache 23 urocortin 120 T lymphocyte 122 tottering mouse 80 valproate 151 transformed migraine 22 vanilloid-1 receptor 101 tricyclic antidepressant 151 vascular permeability 119 trigeminal ganglion 58, 119, 121 vasoactive intestinal polypeptide 72,75, 119 trigeminal ganglion stimulation 121 vasodilation 1,2,6, 7, 10-12, 58, 97, 119, 133 trigeminal nerve, sensory nucleus 124 VCAM-1 152 trigeminal nerve fiber 65, 161 verapamil 152 trigeminal system 91 visual cortex 9, 11 trigeminovascular system 91 visual migraine aura 80 triptan 17, 18, 70 triptan, modes of action 17 4991VV93 59, 134, 135 tumor necrosis factor (TNF) 119 Xenon-clearance technique 7,8 umbilical vein 122 unemployment 23 zolmitriptan 17 169 The PIR-Series Progress in Inflammation Research Homepage: http://www.birkhauser.ch Up-to-date information on the latest developments in the pathology, mechanisms and therapy of inflammatory disease are provided in this monograph series. Areas covered inclu­ de vascular responses, skin inflammation, pain, neuroinflammation, arthritis cartilage and bone, airways inflammation and asthma, allergy, cytokines and inflammatory mediators, cell signalling, and recent advances in drug therapy. Each volume is edited by acknowledged experts providing succinct overviews on specific topics intended to inform and explain. The series is of interest to academic and industrial biomedical researchers, drug development personnel and rheumatologists, allergists, pathologists, dermatologists and other clinicians requiring regular scientific updates. Available volumes: T Cells in Arthritis, P. Miossec, W. van den Berg, G. Firestein (Editors), 1998 Chemokines and Skin, E. Kownatzki, J. Norgauer (Editors), 1998 Medicinal Fatty Acids, J. Kremer (Editor), 1998 Inducible Enzymes in the Inflammatory Response, DA Willoughby, A. Tomlinson (Editors), 1999 Cytokines in Severe Sepsis and Septic Shock, H. Redl,
Load more

Recommended publications
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
    Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency Lääkeaineiden yleisnimet (INN-nimet) 21.6.
    [Show full text]
  • WO 2018/152334 Al 23 August 2018 (23.08.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/152334 Al 23 August 2018 (23.08.2018) W !P O PCT (51) International Patent Classification: (US). YUCEL, Tuna; 28 Monmouth Avenue, Medford, A61K 9/107 (2006.01) A61K 31/352 (2006.01) MA 02155 (US). BOYLAN, Nicholas, J.; 215 Green A61K 47/26 (2006.01) A61K 9/48 (2006.01) Street, Boylston, MA 01505 (US). A61K 47/14 (2006.01) A61K 9/00 (2006.01) (74) Agent: EISENSCHENK, Frank, C. et al; Saliwanchik, A61K 31/05 (2006 .01) A61P 25/06 (2006 .0 1) Lloyd & Eisenschenk, P.O. Box 142950, Gainesville, FL (21) International Application Number: 32614-2950 (US). PCT/US2018/018382 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 15 February 2018 (15.02.2018) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (26) Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/459,086 15 February 2017 (15.02.2017) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/546,149 16 August 2017 (16.08.2017) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, (71) Applicant: MOLECULAR INFUSIONS, LLC [US/US]; TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215
    A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation ISN/Protocol 2215-CL-0301 ClinicalTrials.gov Identifier: NCT02421939 Date of Protocol Version 9.1: 16 May 2018 Sponsor: Astellas Pharma Global Development, Inc. (APGD) 1 Astellas Way Northbrook, IL 60062 Sponsor: APGD ISN/Protocol 2215-CL-0301 EudraCT 2015-000140-42 - CONFIDENTIAL - A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215 ISN/Protocol 2215-CL-0301 Version 9.1 [JP] Incorporating Country-specific Non-Substantial Amendment 3 [See Attachment 1] 16 May 2018 IND 117,548 EudraCT 2015-000140-42 Sponsor: Astellas Pharma Global Development, Inc. (APGD) 1 Astellas Way Northbrook, IL 60062 Protocol History: Version 1.0 [24Mar2015] Version 2.0 Incorporating Substantial Amendment 1 [22Jun2015] Version 2.1 [JP] Incorporating Country-specific Non-Substantial Amendment 1 [06Aug2015] Version 3.0 Incorporating Substantial Amendment 2 [13Aug2015] Version 3.0 [JP] Incorporating Substantial Amendment 2 [13Aug2015] Version 4.0 [KR] Incorporating Country-specific Substantial Amendment 3 [08Oct2015] Version 5.0 Incorporating Substantial Amendment 4 [09Dec2015] Version 5.0 [KR] Incorporating Substantial Amendment 4 [09Dec2015] Version 5.0 [JP] Incorporating Substantial Amendment 4 [09Dec2015] Version 6.0 [KR] Incorporating
    [Show full text]
  • An Efficient Fischer Indole Synthesis of Avitriptan, a Potent 5-HT1D Receptor Agonist
    9192 J. Org. Chem. 1997, 62, 9192-9202 An Efficient Fischer Indole Synthesis of Avitriptan, a Potent 5-HT1D Receptor Agonist Paul R. Brodfuehrer,* Bang-Chi Chen, Thomas R. Sattelberg, Sr., Patrick R. Smith, Jayachandra P. Reddy, Derron R. Stark, Sandra L. Quinlan, and J. Gregory Reid Process Exploration Labs-I, Technical Operations Division, Bristol-Myers Squibb Company, P.O. Box 4755, Syracuse, New York 13221-4755 John K. Thottathil and Shaopeng Wang* Chemical Process Research, Pharmaceutical Research Institute, Bristol-Myers Squibb Company, P.O. Box 191, New Brunswick, New Jersey 08903-0191 Received July 24, 1997X An efficient synthesis of the antimigraine drug candidate avitriptan (1, BMS 180048) is reported. The key step is a two-phase Fischer indolization reaction between hydrazine 6 and 5-chlorovaler- aldehyde, 20, to give the chloropropylindole 35, which is susceptible to acid-catalyzed degradation under the reaction conditions required for its formation. Sequential coupling of 35 with piperazine, 26, and 4-chloro-5-methoxypyrimidine, 24, gives the title compound in 40-45% overall yield. Significant improvements in the syntheses of the known starting materials, hydrazine 6, 5-chlorovaleraldehyde, 20, and 4-chloro-5-methoxypyrimidine, 24, were also achieved. Introduction Scheme 1 Among the many biologically active indoles, serotonin (5-hydroxytriptamine, 5-HT) is known to exhibit antimi- graine activity, and numerous serotonin-like compounds are currently under investigation as 5-HT1D receptor agonists for the treatment of migraine headache. Sumatriptan, 2, is the first of these to be commercialized,1 and several others, including MK 0462, 3,2 L-695,894, 4,3 and avitriptan (1, BMS 180048), are under develop- ment.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • RPCN Content
    Send Orders for Reprints to [email protected] 26 Recent Patents on CNS Drug Discovery, 2014, 9, 26-40 Migraine Attack Treatment: A Tailor-made Suit, Not One Size Fits All Robert Belvís*, Natalia Mas and Azahara Aceituno Headache Unit. Department of Neurology, Quiron Dexeus University Hospital, Barcelona, Spain Received: October 28, 2013; Revised: January 11, 2014; Accepted: February 06, 2014 Abstract: About 15% of people in the world suffer migraine attacks. Migraine can induce a great impact in the quality of life, and the costs of medical care and loss of productivity can be also high. Non-steroidal anti-inflammatory drugs (NSAIDs) are the best treatment in mild-to-moderate migraine attacks and triptans are the first line option in the acute treatment of moderate-to-severe migraine attacks. At present, there are seven marketed triptans: sumatriptan, rizatriptan, zolmitriptan, eletriptan, naratriptan, almotriptan and frovatriptan. Obviously, every drug presents different pharmacoki- netic and pharmacodynamics properties and, moreover, some triptans have several formulations. The prescription of one of these seven triptans for a specified patient is based in the drug profile: efficacy, safety, pharmacokinetics and pharma- codynamics. Other data to take account in the final prescription are clinical characteristics of the migraine attack (speed of onset, intensity of pain, lasting of the attack) and patient characteristics as working habits, life style or medical history. It is therefore mandatory to perform an individualization of the treatment of migraine attack. In recent years, several new patents of drugs have been registered in the treatment of migraine attack, although most of these are already known drugs that only provide new routes of administration.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich Et Al
    US 200400.58896A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich et al. (43) Pub. Date: Mar. 25, 2004 (54) PHARMACEUTICAL PREPARATION (30) Foreign Application Priority Data COMPRISING AN ACTIVE DISPERSED ON A MATRIX Dec. 7, 2000 (EP)........................................ OO126847.3 (76) Inventors: Rango Dietrich, Konstanz (DE); Publication Classification Rudolf Linder, Kontanz (DE); Hartmut Ney, Konstanz (DE) (51) Int. Cl." ...................... A61K 31156; A61K 31/4439 (52) U.S. Cl. ........................... 514/171; 514/179; 514/338 Correspondence Address: (57) ABSTRACT NATH & ASSOCATES PLLC 1030 FIFTEENTH STREET, N.W. The present invention relates to the field of pharmaceutical SIXTH FLOOR technology and describes a novel advantageous preparation WASHINGTON, DC 20005 (US) for an active ingredient. The novel preparation is Suitable for 9 producing a large number of pharmaceutical dosage forms. (21) Appl. No.: 10/433,398 In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix com (22) PCT Filed: Dec. 6, 2001 posed of one or more excipients Selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid (86) PCT No.: PCT/EPO1/14307 eSter. US 2004/0058896 A1 Mar. 25, 2004 PHARMACEUTICAL PREPARATION 0008 Further subject matters are evident from the claims. COMPRISING AN ACTIVE DISPERSED ON A MATRIX 0009. The preparations for the purpose of the invention preferably comprise numerous individual units in which at least one active ingredient particle, preferably a large num TECHNICAL FIELD ber of active ingredient particles, is present in an excipient 0001. The present invention relates to the field of phar matrix composed of the excipients of the invention (also maceutical technology and describes a novel advantageous referred to as active ingredient units hereinafter).
    [Show full text]
  • Florencio Zaragoza Dörwald Lead Optimization for Medicinal Chemists
    Florencio Zaragoza Dorwald¨ Lead Optimization for Medicinal Chemists Related Titles Smith, D. A., Allerton, C., Kalgutkar, A. S., Curry, S. H., Whelpton, R. van de Waterbeemd, H., Walker, D. K. Drug Disposition and Pharmacokinetics and Metabolism Pharmacokinetics in Drug Design From Principles to Applications 2012 2011 ISBN: 978-3-527-32954-0 ISBN: 978-0-470-68446-7 Gad, S. C. (ed.) Rankovic, Z., Morphy, R. Development of Therapeutic Lead Generation Approaches Agents Handbook in Drug Discovery 2012 2010 ISBN: 978-0-471-21385-7 ISBN: 978-0-470-25761-6 Tsaioun, K., Kates, S. A. (eds.) Han, C., Davis, C. B., Wang, B. (eds.) ADMET for Medicinal Chemists Evaluation of Drug Candidates A Practical Guide for Preclinical Development 2011 Pharmacokinetics, Metabolism, ISBN: 978-0-470-48407-4 Pharmaceutics, and Toxicology 2010 ISBN: 978-0-470-04491-9 Sotriffer, C. (ed.) Virtual Screening Principles, Challenges, and Practical Faller, B., Urban, L. (eds.) Guidelines Hit and Lead Profiling 2011 Identification and Optimization ISBN: 978-3-527-32636-5 of Drug-like Molecules 2009 ISBN: 978-3-527-32331-9 Florencio Zaragoza Dorwald¨ Lead Optimization for Medicinal Chemists Pharmacokinetic Properties of Functional Groups and Organic Compounds The Author All books published by Wiley-VCH are carefully produced. Nevertheless, authors, Dr. Florencio Zaragoza D¨orwald editors, and publisher do not warrant the Lonza AG information contained in these books, Rottenstrasse 6 including this book, to be free of errors. 3930 Visp Readers are advised to keep in mind that Switzerland statements, data, illustrations, procedural details or other items may inadvertently be Cover illustration: inaccurate.
    [Show full text]